Related Experiment Video
Updated: May 1, 2026
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
Biomarkers for Monitoring R-CHOP-associated Cardiotoxicity in Patients with Non-hodgkin Lymphoma
G R Gimatdinova1, O E Danilova2, I L Davydkin3
1Department of Hospital Therapy with courses in Hematology and Transfusiology, Hematologist at the Department of Hematology and Chemotherapy No. 2 with the Bone Marrow and Hematopoietic Stem Cell Transplantation Unit at Samara Medical University, Samara, Russia.
Introduction:
Antineoplastic therapy may exert toxic effects on multiple organ systems in patients with hematologic malignancies. This is particularly relevant for individuals with indolent non-Hodgkin lymphoma treated with anthracycline-containing regimens, which carry a well-documented risk of cardiotoxicity.
Materials And Methods:
A case-control study was conducted at medical institutions in Samara, Russia, enrolling 72 patients diagnosed with grade 1-2 follicular B-cell non-Hodgkin lymphoma. All participants were administered six cycles of R-CHOP immunochemotherapy as clinically indicated. The primary objective was to identify early biomarkers of treatment-related cardiotoxicity.
Results:
The study identified three parameters as the most sensitive indicators of cardiovascular toxicity: prolongation of the corrected QT interval (QTc), reduction in left ventricular global longitudinal strain, and elevation of N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) levels. Additionally, the authors propose prognostic models to predict the presence of cardiotoxicity at 3 and 6 months of treatment.
Discussion:
Comparison of the study's findings with previously published data revealed full consistency with the existing medical literature and further substantiates the authors' assertion regarding the prognostic utility of the identified laboratory and instrumental markers in the early detection of cardiotoxicity.
Conclusion:
Incorporating these biomarkers into routine cardiovascular monitoring protocols facilitates early detection of cardiotoxicity in patients with hematologic malignancies, enabling timely therapeutic adjustments and optimizing clinical management.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...